title: Specimen findings and survival after preoperative 252Cf neutron brachytherapy for stage II cervical carcinoma.
abstract: Twenty-seven patients with operable Stage II cervical cancer with a mean diameter tumor of 8.0 cm were studied in a feasibility study using preoperative 252Cf implants plus whole-pelvis radiation to 45 Gy followed by extrafascial total abdominal hysterectomy and bilateral salpingo-oophorectomy 4 to 6 weeks later. Hysterectomy specimens were studied by a set protocol. With the protocol used, 13/27 (51%) specimens and abdominal stagings were negative for residual tumor. The survival rate for the patients with negative findings was 93% at 5 years. In 14/27 (49%) patients the specimens were positive for residual tumor. In contrast, the 5-year survival rate for this group was 46% (P less than 0.001). In these patients several interrelated factors were determined to be of importance, i.e., (1) tumor size greater than 8 cm in maximum diameter, (2) positive or negative residual tumor status, and (3) total dose of radiation given. Survival was lower for larger tumors and specimens were more likely to show residual tumor. A lower treatment dose led to more positive specimens, as well as to poorer survival. While the patients with Stage II disease fared very well when negative specimens were found, further prospective studies of the appropriate treatment for those with positive tumor specimens are needed.
authors.affiliation: Department of Radiation Medicine, University of Kentucky Medical Center, Lexington 40536-0084.
authors.forename: Y
authors.initials: Y
authors.lastname: Maruyama
authors.forename: E
authors.initials: E
authors.lastname: Donaldson
authors.forename: J R
authors.initials: JR
authors.lastname: van Nagell
authors.forename: J
authors.initials: J
authors.lastname: Yoneda
authors.forename: H H
authors.initials: HH
authors.lastname: Gallion
authors.forename: D
authors.initials: D
authors.lastname: Powell
authors.forename: R J
authors.initials: RJ
authors.lastname: Kryscio
mesh_terms: D001918:Brachytherapy / Q000009:adverse effects / Q000379:methods*; D002142:Californium / Q000627:therapeutic use*; D002588:Cesium Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007044:Hysterectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D009502:Neutrons; D011300:Preoperative Care; D011879:Radiotherapy Dosage; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery
chemical_list: D002588:Cesium Radioisotopes; D002142:Californium